Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002155992 | SCV002466174 | benign | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002505834 | SCV002806547 | likely benign | Complement component 5 deficiency; Eculizumab, poor response to | 2021-08-09 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004782897 | SCV005394625 | benign | not specified | 2024-09-25 | criteria provided, single submitter | clinical testing | Variant summary: C5 c.2059+16T>A alters a non-conserved nucleotide located at a position not widely known to affect splicing. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00042 in 249638 control chromosomes. The observed variant frequency is approximately 3.76 fold of the estimated maximal expected allele frequency for a pathogenic variant in C5 causing C5 Deficiency phenotype (0.00011). To our knowledge, no occurrence of c.2059+16T>A in individuals affected with C5 Deficiency and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 1652212). Based on the evidence outlined above, the variant was classified as benign. |